Drug Trial Radar · NCT01208766
Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,503
Actual
Start
Jan 2011
Primary completion
Dec 2020
Study completion Jan 2025
Sponsor
- Lead sponsor
- Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European Myeloma Network B.V.; Gruppo Italiano Malattie EMatologiche dell'Adulto; DSMM (Deutsche Studiengruppe Multiples Myelom); NMSG (Nordic Myeloma Study Group); Central European Myeloma Study Group
- First posted
- Sep 24, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study phase: phase III Study objective: * Comparison of Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed autologous stem cell transplantation (ASCT) * Comparison of Bortezomib, Lenalidomide, Dexamethasone(VRD) as consolidation versus no consolidation * Comparison of single versus tandem high dose Melphalan with ASCT Patient population: Patients with symptomatic multiple myeloma,previously untreated, ISS stages 1-3, age 18-65 years inclusive Study design: Prospective, multicenter, intergroup, randomized Duration of treatment: Expected duration of induction, stem cell collection and intensification is 6 - 9 months. Consolidation with VRD will last 2 months Maintenance therapy with Lenalidomide will be given until relapse. All patients will be followed until 10 years after registration.
Conditions
- Multiple Myeloma
Interventions
Bortezomib, Melphalan, Prednisone (VMP)Drug
* Bortezomib \_ 1.3 mg/m2 \_ i.v. rapid infusion \_ days 1,4,8,11,22,25,29,32 * Melphalan \_ 9 mg/m² \_ p.o. \_ days 1-4 * Prednisone \_ 60 mg/m² \_ p.o. \_ days 1-4
1 or 2 cycle(s) HDM (High Dose Melphalan)Drug
\- Melphalan \_ 100 mg/m² \_ i.v. rapid infusion \_ -3, -2\* \*Patients with renal insufficiency 100 mg/m2 only at day -3 If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR.
2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)Drug
* Bortezomib \_ 1.3 mg/m2 \_ i.v. rapid infusion \_ days 1,4,8,11 * Lenalidomide \_ 25 mg \_ p.o. \_ days 1-21 * Dexamethasone \_ 20 mg \_ p.o. \_ days 1,2,4,5,8,9,11,12
Primary outcomes
What the sponsor says the trial is designed to measure.
- For all registered patients: progression free survival (PFS) as defined by time from registration to progression or death from any cause (whichever occurs first).Time frame: end of trial (last patient last visit)
- For all patients included in R1; PFS as defined by time from randomization R1 to progression or death from any cause whichever comes firstTime frame: end of trial (last patient last visit)
- For all patients included in R2; PFS as defined by time from randomization R2 to progression or death from any cause whichever comes firstTime frame: end of trial (last patient last visit)
Locations
208 sites in 16 countries. Site status is shown where the registry gives one.
AU-Brisbane-PAH
Brisbane, Australia
AU-Canberra-CANBERRAHOSPITAL
Canberra, Australia
AU-Melbourne-ALFRED
Melbourne, Australia
AU-Sydney-CONCORD
Sydney, Australia
AU-Sydney-NEPEAN
Sydney, Australia
Prince of Wales Hospital
Sydney, Australia
St George Hospital
Sydney, Australia
Krankenhaus d.Elisabethinen
Linz, Austria
Landeskrankenhaus Salzburg
Salzburg, Austria
AT-Vienna-HANUSCH
Vienna, Austria
BE-Antwerpen Edegem-UZA
Antwerp, Belgium
BE-Antwerpen-ZNASTUIVENBERG
Antwerp, Belgium
BE-Haine-Saint-Paul-JOLIMONT
Haine-Saint-Paul, Belgium
CHU Tivoli
La Louvière, Belgium
BE-Liege-CHRCITADELLE
Liège, Belgium
BE-Mons-AMBROISE
Mons, Belgium
CHR Saint Joseph
Mons, Belgium
BE-Roeselare-AZDELTA
Roeselare, Belgium
RHMS
Saint-Ghislain, Belgium
CH Wapi
Tournai, Belgium
AZ Turnhout
Turnhout, Belgium
CZ-Brno-UHBRNO
Brno, Czechia
Kralove-University Hospital Hradec Kralove
Hradec, Czechia
CZ-Olomouc-FNOL
Olomouc, Czechia
CZ-Ostrava-Poruba-FNO
Ostrava, Czechia
University Hospital Plzen
Pilsen, Czechia
University Hospital Kralovske Vinohrady
Prague, Czechia
DK-Aalborg-AALBORGUH
Aalborg, Denmark
DK-Aarhus N-AUH
Aarhus, Denmark
DK-Copenhagen-RIGSHOSPITALET
Copenhagen, Denmark
DK-Herlev-HERLEV
Herlev, Denmark
DK-Odense-OUH
Odense, Denmark
DK-Roskilde-ROSKILDE
Roskilde, Denmark
FI-Turku-TYKS
Turku, Finland
GR-Athens-ALEXANDRA
Athens, Greece
St. Istvan and St. Laszlo Korhaz Hospital
Budapest, Hungary
Szeged University Hospital
Szeged, Hungary
SS Antonio e Biogio
Alessandria, Italy
AOU Umberto I-Clinica di Ematologica
Ancona, Italy
Ospedale C. e G. Mazzoni-Ematologia
Ascoli Piceno, Italy
Showing 40 of 208 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.